BIONDVAX PHARMA/S (NASDAQ: BVXV) is one of 106 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare BIONDVAX PHARMA/S to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.
Institutional and Insider Ownership
7.0% of BIONDVAX PHARMA/S shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 6.0% of BIONDVAX PHARMA/S shares are held by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings and price targets for BIONDVAX PHARMA/S and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BIONDVAX PHARMA/S Competitors||641||2219||5389||219||2.61|
As a group, “Biological products, except diagnostic” companies have a potential upside of 35.19%. Given BIONDVAX PHARMA/S’s rivals higher probable upside, analysts clearly believe BIONDVAX PHARMA/S has less favorable growth aspects than its rivals.
This table compares BIONDVAX PHARMA/S and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BIONDVAX PHARMA/S Competitors||-8,316.86%||-75.40%||-24.08%|
Earnings and Valuation
This table compares BIONDVAX PHARMA/S and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BIONDVAX PHARMA/S||N/A||-$9.96 million||-2.79|
|BIONDVAX PHARMA/S Competitors||$1.02 billion||$93.10 million||-4.69|
BIONDVAX PHARMA/S’s rivals have higher revenue and earnings than BIONDVAX PHARMA/S. BIONDVAX PHARMA/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
BIONDVAX PHARMA/S has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S’s rivals have a beta of 1.64, suggesting that their average stock price is 64% more volatile than the S&P 500.
BIONDVAX PHARMA/S rivals beat BIONDVAX PHARMA/S on 8 of the 10 factors compared.
About BIONDVAX PHARMA/S
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.